SARS vaccines: where are we?

Rachel L. Roper; Kristina E. Rehm


Expert Rev Vaccines. 2009;8(7):887-898. 

In This Article


Much research to elucidate potential antigens, routes of vaccination, and methods for the design of SARS vaccines has been completed. Immunogenicity has been widely demonstrated, but identification of correlates of protection, and generation of immune responses that protect from clinical signs and lung damage remain elusive. Results suggest that a protective SARS vaccine should be possible; however, protection in mammals that are susceptible to severe disease (e.g., ferrets and humans) may be more difficult than the mouse models suggest. To date, the data indicate that the most efficacious vaccine strategy might be a heterologous combination of intranasal and systemic vaccination, since each delivers different aspects of protection. Given the incomplete protection of current vaccines, it seems unwise to discount T-cell responses, which have not been adequately evaluated, or the protection that might be afforded by the inclusion of additional viral proteins (especially those displayed on the virion and on the surface of infected cells) in SARS-CoV vaccine development.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: